Structure Therapeutics (GPCR) Shares Outstanding (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Shares Outstanding (Entity) of $213.2 million for Q1 2026, up 23.52% year-over-year from $172.6 million in Q1 2025, and little changed quarter-over-quarter from $212.5 million in Q4 2025.
Structure Therapeutics (GPCR) Shares Outstanding (2022 - 2026) Analysis & Trends
Structure Therapeutics' Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $213.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 23.52% year-over-year to $213.2 million; the TTM figure through Mar 2026 stood at $213.2 million (up 23.52% YoY), while the FY2025 annual figure was $212.5 million, up 23.65% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $213.2 million, roughly flat from $212.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $213.2 million in Q1 2026, with the low at $10.5 million in Q2 2022.
- The 5-year median for Shares Outstanding (Entity) is $139.9 million (2024), against an average of $127.6 million.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) jumped 927.43% in 2023, then grew 0.65% in 2025.
- Structure Therapeutics' Shares Outstanding (Entity) stood at $75.1 million in 2022, then soared by 46.8% to $110.2 million in 2023, then soared by 55.96% to $171.9 million in 2024, then grew by 23.65% to $212.5 million in 2025, then gained by 0.33% to $213.2 million in 2026.
- Business Quant data shows GPCR's Shares Outstanding (Entity) at $213.2 million in Q1 2026, $212.5 million in Q4 2025, and $182.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 217.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217.96 Mn |
| Mar 31, 2026 | 217.33 Mn |
| Dec 31, 2025 | 177.60 Mn |
| Sep 30, 2025 | 175.47 Mn |
| Jun 30, 2025 | 172.65 Mn |
| Mar 31, 2025 | 172.05 Mn |
| Dec 31, 2024 | 157.92 Mn |
| Sep 30, 2024 | 171.63 Mn |
| Jun 30, 2024 | 148.24 Mn |
| Mar 31, 2024 | 139.71 Mn |
| Dec 31, 2023 | 110.20 Mn |
| Sep 30, 2023 | 114.95 Mn |
| Jun 30, 2023 | 114.78 Mn |
| Mar 31, 2023 | 71.89 Mn |
| Dec 31, 2022 | 75.07 Mn |
| Sep 30, 2022 | 10.51 Mn |
| Jun 30, 2022 | 10.90 Mn |
| Mar 31, 2022 | 67.22 Mn |